FDA approves groundbreaking pancreatic cancer pill daraxonrasib

The FDA granted expedited approval to daraxonrasib, a first-of-its-kind pill targeting a mutated protein that drives tumour growth in over 90% of pancreatic cancer cases — the most common form of the disease. Drugmakers have sought this approach for decades without success. The approval offers US patients a more effective treatment against one of the deadliest cancers.